Liraglutide Treatment in Obese Infertile PCOS Women
- Sponsor
- Peking University Third Hospital
- Study ID
- NCT06742710
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Infertility
- Obesity
- PCOS
Eligibility Criteria
- Sex
- FEMALE
- Age
- 20 Years - 40 Years
- Healthy Volunteers
- Not accepted
Interventions
- Liraglutide and metformin — DRUGLiraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.
- Metformin — DRUGMetformin 1500 mg/day until pregnancy
Study Details
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility. Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.
Key Dates
- Start date
- May 22, 2025
- Status verified
- Dec 2024
- Primary completion
- May 30, 2029
- Completion
- Dec 31, 2029
Study Design
- Enrollment
- 890 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Intervention GroupLiraglutide 3.0 mg or maximum tolerable dose/day and metformin 1500 mg/day
- Active Comparator: Control GroupMetformin 1500 mg/day
Primary Outcome Measure
Live birth rate associated with single cycle frozen embryo transfer [ Time Frame: At delivery ]
Central Contacts
- Haining Wang, Professor8601082265025
- Ye Liu, Associate Professor8601082265025
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Study to Create Potential Cell-Based Therapies to Treat Human Disease and DisabilityEnrolling By Invitation · Stanford University · Stanford, California
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona